Journal
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
Volume 339, Issue 6, Pages 580-581Publisher
ELSEVIER SCIENCE INC
DOI: 10.1097/MAJ.0b013e3181dd1aa5
Keywords
Psoriasis; Sunitinib
Categories
Ask authors/readers for more resources
Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available